首页 > 最新文献

Journal of Pharmaceutical Health Care and Sciences最新文献

英文 中文
Impact of polypharmacy on 3-year mortality in patients with heart failure: a retrospective study. 多药治疗对心力衰竭患者 3 年死亡率的影响:一项回顾性研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-02 DOI: 10.1186/s40780-024-00357-7
Daisuke Hayashi, Yoshiaki Kubota, Takuya Nishino, Yukihiro Watanabe, Yoshiki Iwade, Junya Matsuda, Katsuhito Kato, Shuhei Tara, Yuya Ise, Yu-Ki Iwasaki, Kuniya Asai

Background: Guideline-directed medical therapy (GDMT) is important in heart failure management; however, polypharmacy itself may impact heart failure. Although measures against polypharmacy are needed, current discussion on unilateral drug tapering (including the drugs that should be tapered) is insufficient. In this study, we investigated the relationship between the number of prescribed GDMT drugs and prognosis in patients with heart failure.

Methods: In this single-centre retrospective study, 3,146 eligible patients with heart failure were included and divided into four groups based on the median number of prescribed GDMT drugs and the median number of drugs not included in the GDMT (ni-GDMT) at the time of hospital discharge. The definition of GDMT was based on various Japanese guidelines. The primary outcome was all-cause mortality within 3 years of hospital discharge.

Results: A total of 252 deaths were observed during the 3-year follow-up period. Kaplan-Meier analysis revealed that groups with GDMT drug count ≥ 5 and ni-GDMT drug count < 4 had the lowest mortality, and those with GDMT drug count < 5 and ni-GDMT drug count ≥ 4 had the highest mortality (log-rank, P < 0.001). Cox regression analysis revealed a significant association between ni-GDMT drug count and all-cause mortality, even after adjustment for number of GDMT medications, age, male, left ventricular ejection function < 40%, hemoglobin, albumin levels, and estimated glomerular filtration rate [HR = 1.06 (95% CI: 1.01-1.11), P = 0.020]. Conversely, the GDMT drug count was not associated with increased mortality rates.

Conclusions: The ni-GDMT drug count was significantly associated with 3-year mortality in patients with heart failure. Conversely, the GDMT drug count did not worsen the prognosis. Polypharmacy measures should consider ni-GDMT drug quantity to improve the prognosis and outcomes in patients with heart failure.

背景:指南指导下的药物治疗(GDMT)在心力衰竭治疗中非常重要;然而,多药治疗本身可能会对心力衰竭产生影响。虽然需要采取措施应对多药治疗,但目前关于单侧减药(包括应减量的药物)的讨论还不够充分。在这项研究中,我们调查了心力衰竭患者的处方 GDMT 药物数量与预后之间的关系:在这项单中心回顾性研究中,共纳入了 3,146 名符合条件的心衰患者,并根据出院时处方 GDMT 药物数量中位数和未纳入 GDMT 的药物数量中位数(ni-GDMT)将患者分为四组。GDMT 的定义基于日本的各种指南。主要结果是出院后 3 年内的全因死亡率:结果:3 年随访期间共观察到 252 例死亡。Kaplan-Meier分析显示,GDMT药物数≥5组和ni-GDMT药物数≥5组的死亡率均高于ni-GDMT药物数≥5组:ni-GDMT药物数与心衰患者的3年死亡率显著相关。相反,GDMT 药物数不会使预后恶化。多药治疗措施应考虑 ni-GDMT 药物数量,以改善心衰患者的预后和疗效。
{"title":"Impact of polypharmacy on 3-year mortality in patients with heart failure: a retrospective study.","authors":"Daisuke Hayashi, Yoshiaki Kubota, Takuya Nishino, Yukihiro Watanabe, Yoshiki Iwade, Junya Matsuda, Katsuhito Kato, Shuhei Tara, Yuya Ise, Yu-Ki Iwasaki, Kuniya Asai","doi":"10.1186/s40780-024-00357-7","DOIUrl":"10.1186/s40780-024-00357-7","url":null,"abstract":"<p><strong>Background: </strong>Guideline-directed medical therapy (GDMT) is important in heart failure management; however, polypharmacy itself may impact heart failure. Although measures against polypharmacy are needed, current discussion on unilateral drug tapering (including the drugs that should be tapered) is insufficient. In this study, we investigated the relationship between the number of prescribed GDMT drugs and prognosis in patients with heart failure.</p><p><strong>Methods: </strong>In this single-centre retrospective study, 3,146 eligible patients with heart failure were included and divided into four groups based on the median number of prescribed GDMT drugs and the median number of drugs not included in the GDMT (ni-GDMT) at the time of hospital discharge. The definition of GDMT was based on various Japanese guidelines. The primary outcome was all-cause mortality within 3 years of hospital discharge.</p><p><strong>Results: </strong>A total of 252 deaths were observed during the 3-year follow-up period. Kaplan-Meier analysis revealed that groups with GDMT drug count ≥ 5 and ni-GDMT drug count < 4 had the lowest mortality, and those with GDMT drug count < 5 and ni-GDMT drug count ≥ 4 had the highest mortality (log-rank, P < 0.001). Cox regression analysis revealed a significant association between ni-GDMT drug count and all-cause mortality, even after adjustment for number of GDMT medications, age, male, left ventricular ejection function < 40%, hemoglobin, albumin levels, and estimated glomerular filtration rate [HR = 1.06 (95% CI: 1.01-1.11), P = 0.020]. Conversely, the GDMT drug count was not associated with increased mortality rates.</p><p><strong>Conclusions: </strong>The ni-GDMT drug count was significantly associated with 3-year mortality in patients with heart failure. Conversely, the GDMT drug count did not worsen the prognosis. Polypharmacy measures should consider ni-GDMT drug quantity to improve the prognosis and outcomes in patients with heart failure.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"34"},"PeriodicalIF":1.2,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141492348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study. 埃塞俄比亚三级医院中服用华法林的非住院病人的抗凝控制和疗效:一项准实验研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-26 DOI: 10.1186/s40780-024-00355-9
Tamrat Assefa Tadesse, Amha Gebremedhin, Dejuma Yadeta, Legese Chelkeba, Teferi Gedif Fenta

Background: We aimed to compare anticoagulation control and outcomes between usual medical care (UMC) and pharmacist-led anticoagulation services (PLAS) in patients receiving warfarin at the Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia.

Methods: A quasi-experimental study was conducted, including 350 (66.7%) and 175 (33.3%) patients from the UMC and PLAS groups, respectively, from 525 patients. The time in therapeutic range (TTR) was determined using the Rosendaal method, with a TTR ≥ 65% set as the cut-off for optimal anticoagulation. The two-sample Wilcoxon rank-sum (Mann-Whitney U) test was used to compare continuous variables between groups. Categorical variables were compared between groups using Pearson's chi-square test or Fisher's exact test. Logistic regression and negative binomial regression analyses were conducted to identify the factors associated with suboptimal TTR and secondary outcomes, respectively, at the p values < 0.05, and 95% confidence interval (CI).

Results: Compared with the UMC group, the patients in the PLAC group showed a significantly higher median (IQR) TTR [60.89% (43.5-74.69%) vs. 53.65% (33.92-69.14%), p < 0.001]. A significantly higher optimal TTR (≥ 65%) was achieved in the PLAC group (41.7% vs. 31.7%) than in the UMC group (p = 0.002). The odds of having a poor TTR were reduced by 43% (AOR = 0.57, 95% CI = 0.36-0.88, p = 0.01) among patients in the PLAC group compared to those in the UMC group. There were no statistically significant differences in the secondary outcomes between the groups, except for all-cause emergency visits (p = 0.003). The incidence of bleeding events decreased by 3% (IRR = 0.97, 95% CI = 0.96-0.99, p < 0.001) for every increase in INR monitoring frequency. The incidence of thromboembolic events increased by a factor of 15.13 (IRR = 15.13, 95% CI = 1.47-155.52, p = 0.02) among patients with a high-risk CHA2DS2-VASc score compared with those with a moderate score.

Conclusion: Patients in the PLAC group had a significantly higher median TTR than those in the UMC group did. There were no statistically significant differences in the secondary outcomes between the groups, except for fewer all-cause emergency department visits in the PLAC group.

背景我们的目的是比较埃塞俄比亚亚的斯亚贝巴Tikur Anbessa专科医院(TASH)接受华法林治疗的患者在常规医疗护理(UMC)和药剂师指导的抗凝服务(PLAS)之间的抗凝控制和结果:进行了一项准实验研究,从 525 名患者中分别抽取了 350 名(66.7%)和 175 名(33.3%)UMC 组和 PLAS 组患者。采用罗森达尔法测定治疗范围内时间(TTR),以 TTR ≥ 65% 作为最佳抗凝治疗的临界值。两样本 Wilcoxon 秩和 (Mann-Whitney U) 检验用于比较组间连续变量。组间分类变量的比较采用皮尔逊卡方检验或费雪精确检验。进行逻辑回归分析和负二项回归分析,以确定与 TTR 和次要结局相关的因素,分别以 p 值表示 结果:与 UMC 组相比,PLAC 组患者的 TTR 中位数(IQR)明显更高[60.89% (43.5-74.69%) vs. 53.65% (33.92-69.14%), p 2DS2-VASc 评分与中度评分相比:结论:PLAC 组患者的 TTR 中位数明显高于 UMC 组。除了 PLAC 组的全因急诊就诊率较低外,各组间的次要结果无明显统计学差异。
{"title":"Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study.","authors":"Tamrat Assefa Tadesse, Amha Gebremedhin, Dejuma Yadeta, Legese Chelkeba, Teferi Gedif Fenta","doi":"10.1186/s40780-024-00355-9","DOIUrl":"10.1186/s40780-024-00355-9","url":null,"abstract":"<p><strong>Background: </strong>We aimed to compare anticoagulation control and outcomes between usual medical care (UMC) and pharmacist-led anticoagulation services (PLAS) in patients receiving warfarin at the Tikur Anbessa Specialized Hospital (TASH), Addis Ababa, Ethiopia.</p><p><strong>Methods: </strong>A quasi-experimental study was conducted, including 350 (66.7%) and 175 (33.3%) patients from the UMC and PLAS groups, respectively, from 525 patients. The time in therapeutic range (TTR) was determined using the Rosendaal method, with a TTR ≥ 65% set as the cut-off for optimal anticoagulation. The two-sample Wilcoxon rank-sum (Mann-Whitney U) test was used to compare continuous variables between groups. Categorical variables were compared between groups using Pearson's chi-square test or Fisher's exact test. Logistic regression and negative binomial regression analyses were conducted to identify the factors associated with suboptimal TTR and secondary outcomes, respectively, at the p values < 0.05, and 95% confidence interval (CI).</p><p><strong>Results: </strong>Compared with the UMC group, the patients in the PLAC group showed a significantly higher median (IQR) TTR [60.89% (43.5-74.69%) vs. 53.65% (33.92-69.14%), p < 0.001]. A significantly higher optimal TTR (≥ 65%) was achieved in the PLAC group (41.7% vs. 31.7%) than in the UMC group (p = 0.002). The odds of having a poor TTR were reduced by 43% (AOR = 0.57, 95% CI = 0.36-0.88, p = 0.01) among patients in the PLAC group compared to those in the UMC group. There were no statistically significant differences in the secondary outcomes between the groups, except for all-cause emergency visits (p = 0.003). The incidence of bleeding events decreased by 3% (IRR = 0.97, 95% CI = 0.96-0.99, p < 0.001) for every increase in INR monitoring frequency. The incidence of thromboembolic events increased by a factor of 15.13 (IRR = 15.13, 95% CI = 1.47-155.52, p = 0.02) among patients with a high-risk CHA<sub>2</sub>DS<sub>2</sub>-VASc score compared with those with a moderate score.</p><p><strong>Conclusion: </strong>Patients in the PLAC group had a significantly higher median TTR than those in the UMC group did. There were no statistically significant differences in the secondary outcomes between the groups, except for fewer all-cause emergency department visits in the PLAC group.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"32"},"PeriodicalIF":1.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer. 非小细胞肺癌肥胖患者因阿那莫瑞林诱发 QT 间期延长的病例报告。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-26 DOI: 10.1186/s40780-024-00356-8
Hayato Yokota, Ruriko Asahi, Yumiko Akamine, Mizuki Kobayashi, Hiyu Wakabayashi, Sho Sakamoto, Yuji Okuda, Kazuhiro Sato, Katsutoshi Nakayama, Masafumi Kikuchi

Background: Anamorelin, a drug to treat cancer cachexia, binds to ghrelin receptors and improves body weight and appetite. In clinical trials in Japan, patients experienced a 10.7% frequency of stimulant conduction system depression as a severe side effect. Although rare, anamorelin sometimes causes fatal arrhythmias. Because patients with cancer cachexia are often underweight, data on the safety of anamorelin in obese patients are lacking. We report a case of QT interval prolongation after anamorelin administration to an obese patient with non-small cell lung cancer.

Case presentation: A female patient with a body mass index of 30 kg/m2 underwent immunotherapy for lung adenocarcinoma. She presented with severe weight loss, anorexia, and fatigue. She had no history of heart disease. On day 12, after administration of anamorelin 100 mg once daily, the patient developed nausea, diarrhea, and anorexia, which were considered cancer immunotherapy-induced immune-related adverse events, and she was admitted to the hospital. An electrocardiogram (ECG) on admission showed a QTc interval of 502 ms. On admission, her hepatic function was Child-Pugh class B, and anamorelin was discontinued the next day. On day 3 after anamorelin discontinuation, the QTc interval was prolonged by up to 557 ms, then decreased to 490 ms on day 6, and improved to 450 ms on day 16. Re-administration of anamorelin was avoided.

Conclusions: When administering anamorelin to obese patients, we should be aware of the potential for stimulatory conduction system depression, as in underweight patients. Therefore, we should monitor patients by ECG from the early stages of anamorelin administration. Anamorelin is lipophilic, and its volume of distribution is increased in obese patients. Consequently, obese patients may continue to have QT interval prolongation after discontinuation of anamorelin, requiring long-term side-effect monitoring.

背景:阿那莫林是一种治疗癌症恶病质的药物,能与胃泌素受体结合,改善体重和食欲。在日本的临床试验中,患者出现刺激传导系统抑制这一严重副作用的频率为 10.7%。阿那莫瑞林虽然罕见,但有时会导致致命性心律失常。由于癌症恶病质患者通常体重过轻,因此缺乏有关肥胖患者服用阿那莫瑞林安全性的数据。我们报告了一例非小细胞肺癌肥胖患者服用阿莫瑞林后出现 QT 间期延长的病例:一名体重指数为 30 kg/m2 的女性患者接受了肺腺癌免疫治疗。她出现了严重的体重减轻、厌食和乏力。她没有心脏病史。在服用阿那莫瑞林 100 毫克、每天一次后的第 12 天,患者出现了恶心、腹泻和厌食,这被认为是癌症免疫疗法引起的免疫相关不良事件,于是她被送进了医院。入院时的心电图(ECG)显示QTc间期为502毫秒。入院时,她的肝功能为 Child-Pugh B 级,第二天停用了阿莫瑞林。停用阿莫瑞林后的第 3 天,QTc 间期延长达 557 毫秒,第 6 天降至 490 毫秒,第 16 天改善至 450 毫秒。避免了再次使用阿莫瑞林:结论:在对肥胖患者施用阿莫瑞林时,我们应注意刺激传导系统抑制的可能性,就像对体重不足的患者一样。因此,我们应该在使用阿那莫瑞林的早期阶段就通过心电图对患者进行监测。阿那莫瑞林具有亲脂性,其在肥胖患者体内的分布容积会增加。因此,肥胖患者在停用阿那莫瑞林后可能会继续出现 QT 间期延长,需要长期监测其副作用。
{"title":"Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer.","authors":"Hayato Yokota, Ruriko Asahi, Yumiko Akamine, Mizuki Kobayashi, Hiyu Wakabayashi, Sho Sakamoto, Yuji Okuda, Kazuhiro Sato, Katsutoshi Nakayama, Masafumi Kikuchi","doi":"10.1186/s40780-024-00356-8","DOIUrl":"10.1186/s40780-024-00356-8","url":null,"abstract":"<p><strong>Background: </strong>Anamorelin, a drug to treat cancer cachexia, binds to ghrelin receptors and improves body weight and appetite. In clinical trials in Japan, patients experienced a 10.7% frequency of stimulant conduction system depression as a severe side effect. Although rare, anamorelin sometimes causes fatal arrhythmias. Because patients with cancer cachexia are often underweight, data on the safety of anamorelin in obese patients are lacking. We report a case of QT interval prolongation after anamorelin administration to an obese patient with non-small cell lung cancer.</p><p><strong>Case presentation: </strong>A female patient with a body mass index of 30 kg/m2 underwent immunotherapy for lung adenocarcinoma. She presented with severe weight loss, anorexia, and fatigue. She had no history of heart disease. On day 12, after administration of anamorelin 100 mg once daily, the patient developed nausea, diarrhea, and anorexia, which were considered cancer immunotherapy-induced immune-related adverse events, and she was admitted to the hospital. An electrocardiogram (ECG) on admission showed a QTc interval of 502 ms. On admission, her hepatic function was Child-Pugh class B, and anamorelin was discontinued the next day. On day 3 after anamorelin discontinuation, the QTc interval was prolonged by up to 557 ms, then decreased to 490 ms on day 6, and improved to 450 ms on day 16. Re-administration of anamorelin was avoided.</p><p><strong>Conclusions: </strong>When administering anamorelin to obese patients, we should be aware of the potential for stimulatory conduction system depression, as in underweight patients. Therefore, we should monitor patients by ECG from the early stages of anamorelin administration. Anamorelin is lipophilic, and its volume of distribution is increased in obese patients. Consequently, obese patients may continue to have QT interval prolongation after discontinuation of anamorelin, requiring long-term side-effect monitoring.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"33"},"PeriodicalIF":1.2,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of starch granules based on hydroxypropylcellulose as a substitute for excipient lactose. 评估以羟丙基纤维素为基础的淀粉颗粒作为辅料乳糖的替代品。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-21 DOI: 10.1186/s40780-024-00354-w
Tomohiro Yoshikawa, Hiroyo Okamoto, Kenta Takeuchi, Atsushi Hirata, Hiroko Otake, Noriaki Nagai

Background: The improvement in flowability and adhesion of starch powder (SP) is essential for using starch as an excipient for lactose intolerant patients. In this study, we attempted to evaluate the usefulness of hydroxypropylcellulose with molecular weight 80,000 (HPC-80) in the preparation of the starch granules (SG) as a substitute for excipient lactose.

Methods: Hydroxypropylcellulose with molecular weight 30,000 (HPC-30) and HPC-80 were used as binders to prepare the SG, and defined as HPC-30-SG and HPC-80-SG, respectively. Mean particle size (D50) was measured according to the Method, Optical Microscopy of Particle Size Determination in Japanese Pharmacopoeia, Eighteenth Edition, and storage stability were evaluated by measuring of the physical properties after vortexing the granules for 180 s (physical impact). The product loss rate was calculated from the weight change of the various excipients before and after the one dose packaging (ODP).

Results: The D50 of SP (30 µm) was smaller than that of the lactose powder (115 µm). The granulation with 0.75-3% HPC-30 and HPC-80 increased the particle size of SP, and the D50 in 1.5% HPC-30-SG (255 µm) and HPC-80-SG (220 µm) were higher than that of lactose. The excipient was removed from the heat seal of the ODP, and upon visual inspection, a large amount of starchy material was observed to be adhering to the paper in the SP. On the other hand, the low recovery rate in SP was attenuated by the granulation with HPC-30 and HPC-80. In the both HPC-30 and HPC-80, the improvement in recovery rate reached a plateau at 1.5%, and the levels of recovery rate was similar to that of lactose. The recovery rate in the 0.75-3% HPC-30-SG and 0.75% HPC-80-SG were decreased by the physical impact, however, the recovery rate and amount of 1.5% and 3% HPC-80-SG were not affected by the physical impact, and these levels were similar to that of lactose.

Conclusions: The use of HPC-80 as a binder of SG was found to produce a higher quality granule product than conventional HPC-based SG. This finding is useful in streamlining the preparation of starch-based powdered medicine in clinical applications.

背景:要将淀粉用作乳糖不耐受患者的辅料,就必须改善淀粉粉末(SP)的流动性和粘附性。方法:使用分子量为 30,000 的羟丙基纤维素(HPC-30)和 HPC-80 作为粘合剂制备 SG,并分别定义为 HPC-30-SG 和 HPC-80-SG。平均粒度(D50)根据《日本药典》第十八版中的粒度测定光学显微镜法进行测量,贮存稳定性则通过测量颗粒涡旋 180 秒后(物理冲击)的物理性质进行评估。根据一次剂量包装(ODP)前后各种辅料的重量变化计算产品损耗率:结果:SP 的 D50(30 微米)小于乳糖粉的 D50(115 微米)。用 0.75-3% HPC-30 和 HPC-80 制粒后,SP 的粒径增大,1.5% HPC-30-SG (255 µm) 和 HPC-80-SG (220 µm) 的 D50 比乳糖的 D50 大。从 ODP 的热封中取出辅料,目测发现大量淀粉物质附着在 SP 的纸上。另一方面,用 HPC-30 和 HPC-80 制粒后,SP 中的低回收率问题得到了缓解,HPC-30 和 HPC-80 的回收率在 1.5%时达到了一个峰值,回收率水平与乳糖相似。0.75%-3%的HPC-30-SG和0.75%的HPC-80-SG的回收率因物理冲击而下降,但1.5%和3%的HPC-80-SG的回收率和回收量不受物理冲击的影响,其水平与乳糖相似:结论:使用 HPC-80 作为 SG 的粘合剂比传统的 HPC 型 SG 能生产出更高质量的颗粒产品。这一发现有助于在临床应用中简化淀粉基粉末药物的制备过程。
{"title":"Evaluation of starch granules based on hydroxypropylcellulose as a substitute for excipient lactose.","authors":"Tomohiro Yoshikawa, Hiroyo Okamoto, Kenta Takeuchi, Atsushi Hirata, Hiroko Otake, Noriaki Nagai","doi":"10.1186/s40780-024-00354-w","DOIUrl":"10.1186/s40780-024-00354-w","url":null,"abstract":"<p><strong>Background: </strong>The improvement in flowability and adhesion of starch powder (SP) is essential for using starch as an excipient for lactose intolerant patients. In this study, we attempted to evaluate the usefulness of hydroxypropylcellulose with molecular weight 80,000 (HPC-80) in the preparation of the starch granules (SG) as a substitute for excipient lactose.</p><p><strong>Methods: </strong>Hydroxypropylcellulose with molecular weight 30,000 (HPC-30) and HPC-80 were used as binders to prepare the SG, and defined as HPC-30-SG and HPC-80-SG, respectively. Mean particle size (D50) was measured according to the Method, Optical Microscopy of Particle Size Determination in Japanese Pharmacopoeia, Eighteenth Edition, and storage stability were evaluated by measuring of the physical properties after vortexing the granules for 180 s (physical impact). The product loss rate was calculated from the weight change of the various excipients before and after the one dose packaging (ODP).</p><p><strong>Results: </strong>The D50 of SP (30 µm) was smaller than that of the lactose powder (115 µm). The granulation with 0.75-3% HPC-30 and HPC-80 increased the particle size of SP, and the D50 in 1.5% HPC-30-SG (255 µm) and HPC-80-SG (220 µm) were higher than that of lactose. The excipient was removed from the heat seal of the ODP, and upon visual inspection, a large amount of starchy material was observed to be adhering to the paper in the SP. On the other hand, the low recovery rate in SP was attenuated by the granulation with HPC-30 and HPC-80. In the both HPC-30 and HPC-80, the improvement in recovery rate reached a plateau at 1.5%, and the levels of recovery rate was similar to that of lactose. The recovery rate in the 0.75-3% HPC-30-SG and 0.75% HPC-80-SG were decreased by the physical impact, however, the recovery rate and amount of 1.5% and 3% HPC-80-SG were not affected by the physical impact, and these levels were similar to that of lactose.</p><p><strong>Conclusions: </strong>The use of HPC-80 as a binder of SG was found to produce a higher quality granule product than conventional HPC-based SG. This finding is useful in streamlining the preparation of starch-based powdered medicine in clinical applications.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"31"},"PeriodicalIF":1.2,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis. 罗沙司他的使用与甲状腺功能抑制之间的关系:系统回顾和荟萃分析。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-08 DOI: 10.1186/s40780-024-00351-z
Yuki Nakano, Satoru Mitsuboshi, Kazuhiro Tada, Kosuke Masutani

Background: Based on several case reports and observational studies, there is a growing concern regarding the potential association between roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, and suppression of thyroid function. In this systematic review and meta-analysis (PROSPERO: CRD42023471516), we aimed to evaluate the relationship between roxadustat use and suppression of thyroid function.

Methods: We conducted a comprehensive search of MEDLINE via PubMed, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials databases using the search term "roxadustat" to identify all relevant studies. The study population comprised adults with renal anemia who participated in a randomized controlled trial or observational study, with roxadustat as the intervention and a placebo or erythropoiesis-stimulating agent (ESA) as the comparator. The primary outcome was suppression of thyroid function and the secondary outcome was hypothyroidism. A meta-analysis was conducted using the DerSimonian-Laird random effects model based on the size of the intention-to-treat population, and the odds ratio (OR) and 95% confidence interval (CI) were calculated. Two reviewers independently screened the articles, extracted data, and assessed studies using the ROBINS-I tool.

Results: Of the six studies eligible for inclusion, a meta-analysis was performed using data from two observational studies comparing roxadustat and ESA. The meta-analysis showed that the incidence of suppression of thyroid function was significantly higher with roxadustat use than with ESA use (OR: 6.45; 95% CI: 3.39-12.27; I2 = 12%). Compared with ESA, roxadustat seemed to potentially increase the risk for suppression of thyroid function in patients with renal anemia.

Conclusions: Our findings highlighted the importance of monitoring thyroid function in patients treated with roxadustat. The results of this review may enhance the safety of using roxadustat to treat renal anemia through advance recognition of the risk for suppression of thyroid function.

背景:根据一些病例报告和观察性研究,人们越来越关注低氧诱导因子脯氨酰羟化酶抑制剂罗沙司他与甲状腺功能抑制之间的潜在关联。在这项系统综述和荟萃分析(PROSPERO:CRD42023471516)中,我们旨在评估罗沙司他的使用与甲状腺功能抑制之间的关系:我们通过 PubMed、ClinicalTrials.gov 和 Cochrane Central Register of Controlled Trials 数据库对 MEDLINE 进行了全面检索,检索词为 "roxadustat",以确定所有相关研究。研究人群包括参与随机对照试验或观察性研究的肾性贫血成人患者,以罗沙司他作为干预措施,以安慰剂或促红细胞生成剂(ESA)作为比较对象。主要结果是甲状腺功能抑制,次要结果是甲状腺功能减退。根据意向治疗人群的规模,采用DerSimonian-Laird随机效应模型进行了荟萃分析,并计算了几率比(OR)和95%置信区间(CI)。两名审稿人独立筛选文章、提取数据,并使用 ROBINS-I 工具对研究进行评估:在符合纳入条件的六项研究中,利用两项观察性研究的数据进行了荟萃分析,对罗沙度他和ESA进行了比较。荟萃分析表明,使用罗沙司他导致甲状腺功能抑制的发生率明显高于使用ESA(OR:6.45;95% CI:3.39-12.27;I2 = 12%)。与ESA相比,罗沙司他似乎有可能增加肾性贫血患者甲状腺功能抑制的风险:我们的研究结果强调了监测罗沙司他治疗患者甲状腺功能的重要性。本综述的结果可能会提高使用罗沙司他治疗肾性贫血的安全性,因为它能提前识别甲状腺功能抑制的风险。
{"title":"Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis.","authors":"Yuki Nakano, Satoru Mitsuboshi, Kazuhiro Tada, Kosuke Masutani","doi":"10.1186/s40780-024-00351-z","DOIUrl":"10.1186/s40780-024-00351-z","url":null,"abstract":"<p><strong>Background: </strong>Based on several case reports and observational studies, there is a growing concern regarding the potential association between roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, and suppression of thyroid function. In this systematic review and meta-analysis (PROSPERO: CRD42023471516), we aimed to evaluate the relationship between roxadustat use and suppression of thyroid function.</p><p><strong>Methods: </strong>We conducted a comprehensive search of MEDLINE via PubMed, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials databases using the search term \"roxadustat\" to identify all relevant studies. The study population comprised adults with renal anemia who participated in a randomized controlled trial or observational study, with roxadustat as the intervention and a placebo or erythropoiesis-stimulating agent (ESA) as the comparator. The primary outcome was suppression of thyroid function and the secondary outcome was hypothyroidism. A meta-analysis was conducted using the DerSimonian-Laird random effects model based on the size of the intention-to-treat population, and the odds ratio (OR) and 95% confidence interval (CI) were calculated. Two reviewers independently screened the articles, extracted data, and assessed studies using the ROBINS-I tool.</p><p><strong>Results: </strong>Of the six studies eligible for inclusion, a meta-analysis was performed using data from two observational studies comparing roxadustat and ESA. The meta-analysis showed that the incidence of suppression of thyroid function was significantly higher with roxadustat use than with ESA use (OR: 6.45; 95% CI: 3.39-12.27; I<sup>2</sup> = 12%). Compared with ESA, roxadustat seemed to potentially increase the risk for suppression of thyroid function in patients with renal anemia.</p><p><strong>Conclusions: </strong>Our findings highlighted the importance of monitoring thyroid function in patients treated with roxadustat. The results of this review may enhance the safety of using roxadustat to treat renal anemia through advance recognition of the risk for suppression of thyroid function.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"30"},"PeriodicalIF":1.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11161933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient. 一例成功应用缬更昔洛韦治疗药物监测预防肺移植受者巨细胞病毒感染的病例。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-07 DOI: 10.1186/s40780-024-00352-y
Yoshiki Katada, Keisuke Umemura, Shunsaku Nakagawa, Yurie Katsube, Masahiro Tsuda, Satona Tanaka, Hiroshi Date, Miki Nagao, Tomohiro Terada

Background: Ganciclovir and its prodrug, valganciclovir, are first-line agents for cytomegalovirus infection prophylaxis after lung transplantation. Although valganciclovir prophylaxis is known to result in severe leukopenia as an adverse effect, dosage adjustment based on therapeutic drug monitoring (TDM) of ganciclovir concentration is not generally implemented in clinical practice.

Case presentation: In this report, we describe the case of a female in her fifties after lung transplantation who successfully maintained valganciclovir prophylaxis under TDM with a minimal occurrence of severe leukopenia. Valganciclovir administration was initiated at a conventional dose of 450 mg/day on postoperative day 43 but was reduced to 450 mg/2 days on postoperative day 69 because of a decrease in white blood cell count and an increase in trough ganciclovir concentration. Subsequently, the valganciclovir dose adjustment was switched from label-indicated renal function-guided dosing to TDM-based dosing, targeting a trough level of 300-800 ng/mL. This target range was determined through deliberations with infectious disease specialists and pharmacists based on previously reported data. The TDM-based dose adjustment successfully prevented cytomegalovirus reactivation without causing significant adverse effects. Valganciclovir prophylaxis was completed on postoperative day 256, and the patient was transferred to another hospital for rehabilitation.

Conclusions: The findings of the present case suggest that TDM-based dosing could be helpful for clinicians in optimizing the prophylactic administration of valganciclovir in patients undergoing lung transplantation.

背景:更昔洛韦及其原药缬更昔洛韦是肺移植后预防巨细胞病毒感染的一线药物。尽管已知缬更昔洛韦预防性治疗会导致严重的白细胞减少症这一不良反应,但临床实践中一般不会根据更昔洛韦浓度的治疗药物监测(TDM)来调整剂量:在本报告中,我们描述了一例 50 多岁的女性肺移植术后病例,她成功地在 TDM 下维持了缬更昔洛韦的预防性用药,并且极少出现严重的白细胞减少症。缬更昔洛韦于术后第 43 天开始以 450 毫克/天的常规剂量给药,但由于白细胞计数下降和更昔洛韦谷浓度升高,缬更昔洛韦于术后第 69 天降至 450 毫克/2 天。随后,缬更昔洛韦的剂量调整从标签指示的肾功能指导剂量改为基于 TDM 的剂量,目标是达到 300-800 纳克/毫升的谷值水平。这一目标范围是根据之前报告的数据,经传染病专家和药剂师商议后确定的。基于 TDM 的剂量调整成功地防止了巨细胞病毒的再激活,且不会造成明显的不良反应。术后第 256 天,缬更昔洛韦预防治疗结束,患者被转到另一家医院进行康复治疗:本病例的研究结果表明,基于 TDM 的剂量可以帮助临床医生优化肺移植患者的缬更昔洛韦预防性用药。
{"title":"A case of successful contribution of therapeutic drug monitoring of valganciclovir as the prophylaxis against cytomegalovirus infection in a lung transplant recipient.","authors":"Yoshiki Katada, Keisuke Umemura, Shunsaku Nakagawa, Yurie Katsube, Masahiro Tsuda, Satona Tanaka, Hiroshi Date, Miki Nagao, Tomohiro Terada","doi":"10.1186/s40780-024-00352-y","DOIUrl":"10.1186/s40780-024-00352-y","url":null,"abstract":"<p><strong>Background: </strong>Ganciclovir and its prodrug, valganciclovir, are first-line agents for cytomegalovirus infection prophylaxis after lung transplantation. Although valganciclovir prophylaxis is known to result in severe leukopenia as an adverse effect, dosage adjustment based on therapeutic drug monitoring (TDM) of ganciclovir concentration is not generally implemented in clinical practice.</p><p><strong>Case presentation: </strong>In this report, we describe the case of a female in her fifties after lung transplantation who successfully maintained valganciclovir prophylaxis under TDM with a minimal occurrence of severe leukopenia. Valganciclovir administration was initiated at a conventional dose of 450 mg/day on postoperative day 43 but was reduced to 450 mg/2 days on postoperative day 69 because of a decrease in white blood cell count and an increase in trough ganciclovir concentration. Subsequently, the valganciclovir dose adjustment was switched from label-indicated renal function-guided dosing to TDM-based dosing, targeting a trough level of 300-800 ng/mL. This target range was determined through deliberations with infectious disease specialists and pharmacists based on previously reported data. The TDM-based dose adjustment successfully prevented cytomegalovirus reactivation without causing significant adverse effects. Valganciclovir prophylaxis was completed on postoperative day 256, and the patient was transferred to another hospital for rehabilitation.</p><p><strong>Conclusions: </strong>The findings of the present case suggest that TDM-based dosing could be helpful for clinicians in optimizing the prophylactic administration of valganciclovir in patients undergoing lung transplantation.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"28"},"PeriodicalIF":1.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11157855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient satisfaction with pharmacy services among users and non users of community based health insurance scheme at public health facilities in Gamo Zone, South Ethiopia: a comparative cross sectional study. 埃塞俄比亚南部加莫区公立医疗机构中社区医疗保险计划用户和非用户对药房服务的满意度:一项横断面比较研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-07 DOI: 10.1186/s40780-024-00350-0
Fitsum Teferi Gulta, Tidenek Mulugeta, Biruk Wogayehu, Mende Mensa

Background: Patient satisfaction is a crucial humanistic outcome metric in pharmacy services. There was a lack of evidence on patients' satisfaction with pharmacy services in Gamo zone among users and nonusers of the CBHI scheme. Therefore, the aim this study is to compare the level of patient satisfaction with pharmacy services among users and nonusers of community based health insurance scheme at public health facilities in Gamo zone, South Ethiopia.

Method: A facility based comparative cross sectional study design with mixed approach was conducted from June 1 to 30, 2023. A total of 522 study participants and 16 key informants were included as the sample size for quantitative and qualitative study, respectively. The quantitative data was gathered from the study participants who visited the outpatient pharmacy department during the study period by using a simple random sampling technique, while the purposive sampling technique was used to select clients and key informants for the qualitative study. The adjusted odds ratio (AOR) was used to measure the association between independent variables and patient satisfaction toward outpatient pharmacy services at the P values < 0.05 and 95% confidence interval (CI).

Results: From the total of study participants, 195 (73.9%) of insured and 175 (67.8%) of noninsured clients were satisfied with pharmacy services offered at public health facilities. The gender of insured (95% CI = 2.00-12.36, (p 0.01)), and noninsured (95% CI = 0.658-2.881, (p 0.02)), waiting time of insured (95% CI = 0.057-0.766, (p 0.0027)), and noninsured (95% CI = 0.084-0.925, (p 0. 0021)) and premium affordability of insured (95% CI = 0.0605-4.860, (p 0.00)) were significantly associated factors with client satisfaction at p < 0.05 and 95% CI. Based on qualitative finding, as member of the CBHI scheme, the members had a greater opportunity to receive a good pharmacy services, because they were more familiar with the physicians and the institutions.

Conclusion: The clients with insurance perceived high level of satisfaction with pharmacy services in public health facilities than noninsured. The gender and waiting times at outpatient pharmacy department for both groups of study participants and the premium affordability for the insured groups of clients were factors affecting client satisfactions with pharmacy services.

背景:患者满意度是衡量药房服务的重要人文指标。在加莫区,社区医疗保险计划使用者和非使用者对药房服务的满意度缺乏证据。因此,本研究旨在比较埃塞俄比亚南部加莫地区公共医疗机构中社区医疗保险计划使用者和非使用者对药房服务的满意度:方法:2023 年 6 月 1 日至 30 日,采用混合方法进行了一项以医疗机构为基础的横断面比较研究。共有 522 名研究参与者和 16 名关键信息提供者分别作为定量和定性研究的样本量。定量研究采用简单随机抽样技术,从研究期间到药剂科门诊就诊的研究参与者中收集数据;定性研究则采用目的性抽样技术,选择客户和关键信息提供者。采用调整后的几率比(AOR)来衡量自变量与患者对门诊药房服务满意度之间的关系,P 值为 结果:在所有研究参与者中,195 名(73.9%)参保患者和 175 名(67.8%)非参保患者对公立医疗机构提供的药学服务表示满意。投保人(95% CI = 2.00-12.36,(P 0.01))和非投保人(95% CI = 0.658-2.881,(P 0.02))的性别、投保人(95% CI = 0.057-0.766,(P 0.0027))和非投保人(95% CI = 0.084-0.925,(P 0. 0021))和投保人的保费负担能力(95% CI = 0.0605-4.860,(P 0.00))与客户满意度显著相关(P 结论):与未参保者相比,参保者对公立医疗机构药房服务的满意度较高。两组研究参与者的性别和在门诊药房等待的时间,以及投保群体的保费负担能力,都是影响客户对药房服务满意度的因素。
{"title":"Patient satisfaction with pharmacy services among users and non users of community based health insurance scheme at public health facilities in Gamo Zone, South Ethiopia: a comparative cross sectional study.","authors":"Fitsum Teferi Gulta, Tidenek Mulugeta, Biruk Wogayehu, Mende Mensa","doi":"10.1186/s40780-024-00350-0","DOIUrl":"10.1186/s40780-024-00350-0","url":null,"abstract":"<p><strong>Background: </strong>Patient satisfaction is a crucial humanistic outcome metric in pharmacy services. There was a lack of evidence on patients' satisfaction with pharmacy services in Gamo zone among users and nonusers of the CBHI scheme. Therefore, the aim this study is to compare the level of patient satisfaction with pharmacy services among users and nonusers of community based health insurance scheme at public health facilities in Gamo zone, South Ethiopia.</p><p><strong>Method: </strong>A facility based comparative cross sectional study design with mixed approach was conducted from June 1 to 30, 2023. A total of 522 study participants and 16 key informants were included as the sample size for quantitative and qualitative study, respectively. The quantitative data was gathered from the study participants who visited the outpatient pharmacy department during the study period by using a simple random sampling technique, while the purposive sampling technique was used to select clients and key informants for the qualitative study. The adjusted odds ratio (AOR) was used to measure the association between independent variables and patient satisfaction toward outpatient pharmacy services at the P values < 0.05 and 95% confidence interval (CI).</p><p><strong>Results: </strong>From the total of study participants, 195 (73.9%) of insured and 175 (67.8%) of noninsured clients were satisfied with pharmacy services offered at public health facilities. The gender of insured (95% CI = 2.00-12.36, (p 0.01)), and noninsured (95% CI = 0.658-2.881, (p 0.02)), waiting time of insured (95% CI = 0.057-0.766, (p 0.0027)), and noninsured (95% CI = 0.084-0.925, (p 0. 0021)) and premium affordability of insured (95% CI = 0.0605-4.860, (p 0.00)) were significantly associated factors with client satisfaction at p < 0.05 and 95% CI. Based on qualitative finding, as member of the CBHI scheme, the members had a greater opportunity to receive a good pharmacy services, because they were more familiar with the physicians and the institutions.</p><p><strong>Conclusion: </strong>The clients with insurance perceived high level of satisfaction with pharmacy services in public health facilities than noninsured. The gender and waiting times at outpatient pharmacy department for both groups of study participants and the premium affordability for the insured groups of clients were factors affecting client satisfactions with pharmacy services.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"29"},"PeriodicalIF":1.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11162080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with incomplete adherence to integrase strand transfer inhibitor-containing single-tablet regimen among Japanese people living with HIV. 日本艾滋病病毒感染者未完全坚持使用含整合酶链转移抑制剂的单一片剂疗法的相关因素。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-05 DOI: 10.1186/s40780-024-00349-7
Yusuke Kunimoto, Shinichi Hikasa, Masashi Ishihara, Mariko Tsukiji, Kazuko Nobori, Takeshi Kimura, Kenta Onishi, Yuuki Yamamoto, Kyohei Haruta, Yohei Kasiwabara, Kenji Fujii, Masahide Fukudo

Background: People living with human immunodeficiency virus (PLWH) require high rates of medication adherence to antiretroviral therapy (ART) for a successful treatment outcome. Understanding the factors associated with incomplete adherence among those receiving integrase strand transfer inhibitor-containing single-tablet regimens (INSTI-STRs) is crucial for improving treatment outcomes. This study aimed to identify the factors contributing to incomplete ART adherence among Japanese PLWH receiving INSTI-STRs.

Methods: This multicenter cross-sectional study was conducted at 11 Japanese institutions as an anonymous survey. ART adherence was assessed using a self-reported questionnaire. We defined incomplete ART adherence as missing ≥ 1 dose of antiretroviral drugs (ARVs) over the past month. The factors associated with incomplete ART adherence were assessed using logistic regression analysis. Additionally, we investigated the associations between patients' satisfaction score with and need for ARVs and their adherence to ART.

Results: The final analysis included data of 387 patients who were treated with INSTI-STRs. Multivariate logistic regression demonstrated significant association of younger age (adjusted odds ratio [aOR], 0.79; 95%confidence interval [CI]: 0.64-0.99 for each 10-year increment) with incomplete ART adherence. Additionally, female sex (aOR, 3.98; 95%CI: 1.36-11.60); depressive symptoms (mild depression: aOR, 1.68; 95%CI: 1.001-2.82, moderate depression: aOR, 2.98; 95%CI: 1.35-6.53, and severe depression: aOR, 8.73; 95%CI: 1.38-55.00 vs. minimal depression); were also significantly associated with incomplete ART adherence when compared with the reference categories. Concomitant medication usage was significantly associated with a lower rate of incomplete ART adherence (1-4 medications: aOR, 0.53; 95%CI: 0.31-0.89 and ≥ 5 medications: aOR, 0.30; 95%CI: 0.13-0.70 vs. no concomitant medication usage). In the incomplete ART adherence group, satisfaction scores for various aspects were significantly lower. Furthermore, a lower proportion of patients in the incomplete ART adherence group preferred the option of "taking tablets daily and visiting the hospital every 3 months," compared to those in the complete ART adherence group (p = 0.008).

Conclusions: This study demonstrated that factors associated with incomplete ART adherence include younger age, female sex, no concomitant medication, and depressive symptoms. Despite ART simplification, incomplete adherence among PLWH receiving INSTI-STRs, remains a challenge, requiring additional actions.

背景:人类免疫缺陷病毒感染者(PLWH)需要较高的抗逆转录病毒疗法(ART)用药依从性才能获得成功的治疗结果。了解接受含整合酶链转移抑制剂单片治疗方案(INSTI-STR)的患者未完全坚持用药的相关因素对于改善治疗效果至关重要。本研究旨在确定导致接受 INSTI-STRs 治疗的日本 PLWH 不完全坚持抗逆转录病毒疗法的因素:这项多中心横断面研究以匿名调查的形式在日本 11 家机构进行。抗逆转录病毒疗法的依从性通过自我报告问卷进行评估。我们将过去一个月内缺失≥1次抗逆转录病毒药物(ARVs)剂量定义为未完全坚持抗逆转录病毒疗法。我们使用逻辑回归分析评估了与抗逆转录病毒疗法不完全依从相关的因素。此外,我们还调查了患者对抗逆转录病毒药物的满意度和需求与坚持抗逆转录病毒疗法之间的关系:最终分析包括 387 名接受 INSTI-STRs 治疗的患者的数据。多变量逻辑回归结果表明,年龄较小与坚持抗逆转录病毒治疗有显著相关性(调整后的几率比 [aOR],0.79;95% 置信区间 [CI],0.64-0.99):0.64-0.99)。此外,与参考类别相比,女性性别(aOR,3.98;95%CI:1.36-11.60)、抑郁症状(轻度抑郁:aOR,1.68;95%CI:1.001-2.82;中度抑郁:aOR,2.98;95%CI:1.35-6.53;重度抑郁:aOR,8.73;95%CI:1.38-55.00 与轻度抑郁相比)也与抗逆转录病毒疗法的不完全依从性显著相关。同时用药与较低的抗逆转录病毒疗法不完全依从率明显相关(1-4 种药物:aOR,0.53;95%CI:0.31-0.89;≥ 5 种药物:aOR,0.30;95%CI:0.13-0.70 vs. 无同时用药)。在未完全坚持抗逆转录病毒疗法组中,各方面的满意度评分都明显较低。此外,与完全坚持抗逆转录病毒疗法组相比,不完全坚持抗逆转录病毒疗法组中选择 "每天服药,每三个月去医院一次 "的患者比例较低(P = 0.008):本研究表明,与不完全坚持抗逆转录病毒疗法相关的因素包括年龄较小、女性、未同时服用药物和抑郁症状。尽管简化了抗逆转录病毒疗法,但在接受 INSTI-STRs 治疗的 PLWH 中,不完全坚持抗逆转录病毒疗法仍是一项挑战,需要采取更多措施。
{"title":"Factors associated with incomplete adherence to integrase strand transfer inhibitor-containing single-tablet regimen among Japanese people living with HIV.","authors":"Yusuke Kunimoto, Shinichi Hikasa, Masashi Ishihara, Mariko Tsukiji, Kazuko Nobori, Takeshi Kimura, Kenta Onishi, Yuuki Yamamoto, Kyohei Haruta, Yohei Kasiwabara, Kenji Fujii, Masahide Fukudo","doi":"10.1186/s40780-024-00349-7","DOIUrl":"10.1186/s40780-024-00349-7","url":null,"abstract":"<p><strong>Background: </strong>People living with human immunodeficiency virus (PLWH) require high rates of medication adherence to antiretroviral therapy (ART) for a successful treatment outcome. Understanding the factors associated with incomplete adherence among those receiving integrase strand transfer inhibitor-containing single-tablet regimens (INSTI-STRs) is crucial for improving treatment outcomes. This study aimed to identify the factors contributing to incomplete ART adherence among Japanese PLWH receiving INSTI-STRs.</p><p><strong>Methods: </strong>This multicenter cross-sectional study was conducted at 11 Japanese institutions as an anonymous survey. ART adherence was assessed using a self-reported questionnaire. We defined incomplete ART adherence as missing ≥ 1 dose of antiretroviral drugs (ARVs) over the past month. The factors associated with incomplete ART adherence were assessed using logistic regression analysis. Additionally, we investigated the associations between patients' satisfaction score with and need for ARVs and their adherence to ART.</p><p><strong>Results: </strong>The final analysis included data of 387 patients who were treated with INSTI-STRs. Multivariate logistic regression demonstrated significant association of younger age (adjusted odds ratio [aOR], 0.79; 95%confidence interval [CI]: 0.64-0.99 for each 10-year increment) with incomplete ART adherence. Additionally, female sex (aOR, 3.98; 95%CI: 1.36-11.60); depressive symptoms (mild depression: aOR, 1.68; 95%CI: 1.001-2.82, moderate depression: aOR, 2.98; 95%CI: 1.35-6.53, and severe depression: aOR, 8.73; 95%CI: 1.38-55.00 vs. minimal depression); were also significantly associated with incomplete ART adherence when compared with the reference categories. Concomitant medication usage was significantly associated with a lower rate of incomplete ART adherence (1-4 medications: aOR, 0.53; 95%CI: 0.31-0.89 and ≥ 5 medications: aOR, 0.30; 95%CI: 0.13-0.70 vs. no concomitant medication usage). In the incomplete ART adherence group, satisfaction scores for various aspects were significantly lower. Furthermore, a lower proportion of patients in the incomplete ART adherence group preferred the option of \"taking tablets daily and visiting the hospital every 3 months,\" compared to those in the complete ART adherence group (p = 0.008).</p><p><strong>Conclusions: </strong>This study demonstrated that factors associated with incomplete ART adherence include younger age, female sex, no concomitant medication, and depressive symptoms. Despite ART simplification, incomplete adherence among PLWH receiving INSTI-STRs, remains a challenge, requiring additional actions.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"27"},"PeriodicalIF":1.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11151521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report. 尽管出现了严重的免疫相关不良事件,IV 期肾癌患者在服用两个疗程的伊匹单抗加 nivolumab 后仍获得了病理完全应答:病例报告。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-31 DOI: 10.1186/s40780-024-00348-8
Ryo Takada, Miki Fujiwara, Masatoshi Maki, Naoyuki Nomura, Shintaro Kono, Akira Fujita, Hiroshi Masumoto, Yoko Takahashi, Yasuhisa Hasegawa, Koji Tamura

Background: Ipilimumab (Ipi) plus nivolumab (Nivo) is the recommended first-line treatment for renal cell carcinoma (RCC). This report describes a case where pancreatic metastases disappeared after only two courses of Ipi + Nivo therapy. The primary tumor was cured by surgery, and a pathological Complete Response (pCR) was observed despite multiple serious immune-related Adverse Events (irAEs).

Case presentation: A 54-year-old woman with RCC and pancreatic metastasis at stage IV, diagnosed with intermediate risk according to the International Metastatic RCC Database Consortium classification, underwent initiation of Ipi + Nivo therapy. On day 26, she developed hyperthyroidism accompanied by tachycardia, leading to the commencement of metoprolol tartrate treatment. Following the resolution of tachycardia, a second course of Ipi + Nivo therapy was administered on day 50. By day 70, the patient exhibited Grade 3 hepatic dysfunction, followed by the onset of hypothyroidism on day 75, necessitating treatment with steroids and levothyroxine. After positive treatment, a Grade 3 skin disorder emerged on day 87 while tapering steroids, prompting treatment with methylprednisolone (mPSL) pulse therapy. The skin disorder responded to steroids, allowing for tapering. However, on day 113, a recurrence of Grade 3 skin disorder occurred, necessitating another mPSL pulse. The patient responded well to treatment, exhibiting improvement in her condition. On day 131, she presented at the hospital with complaints of respiratory distress, prompting a Computed Tomography (CT) scan that revealed interstitial pneumonia. By day 272, subsequent CT imaging showed the disappearance of pancreatic metastasis and shrinkage of the primary tumor. On day 294, she underwent a laparoscopic left nephrectomy. Pathological analysis confirmed a pCR in the primary tumor, indicating successful eradication of RCC through surgical intervention.

Conclusions: This case report presents a scenario where multiple severe irAEs appeared in a patient, yet metastases disappeared after only two courses of Ipi + Nivo therapy. The patient was ultimately cured by surgery and achieved a pCR. This case highlights that despite the occurrence of severe irAEs during RCC treatment with Ipi + Nivo therapy, they can be managed appropriately to maximize the therapeutic effects of checkpoint inhibitors.

背景:伊匹单抗(Ipilimumab,Ipi)+尼妥珠单抗(nivolumab,Nivo)是治疗肾细胞癌(RCC)的推荐一线疗法。本报告描述了一个病例,患者仅接受了两个疗程的 Ipi + Nivo 治疗后,胰腺转移灶就消失了。尽管发生了多起严重的免疫相关不良事件(irAEs),但手术治愈了原发肿瘤,并观察到病理完全应答(pCR):一名 54 岁的女性患者,患有 RCC 和胰腺转移,处于 IV 期,根据国际转移性 RCC 数据库联盟的分类被诊断为中危,接受了 Ipi + Nivo 治疗。第 26 天,她出现甲状腺功能亢进并伴有心动过速,因此开始使用酒石酸美托洛尔治疗。心动过速缓解后,在第 50 天开始了第二个疗程的 Ipi + Nivo 治疗。第 70 天,患者出现 3 级肝功能障碍,第 75 天出现甲状腺功能减退,需要使用类固醇和左甲状腺素治疗。经过积极治疗后,第 87 天,患者在逐渐减少类固醇用量时出现了 3 级皮肤病,因此需要使用甲基强的松龙(mPSL)脉冲疗法。皮肤病对类固醇有反应,因此可以减量。然而,在第 113 天,3 级皮肤病复发,需要再次使用甲泼尼龙脉冲疗法。患者对治疗反应良好,病情有所改善。第 131 天,她因呼吸困难到医院就诊,并接受了计算机断层扫描(CT),结果显示她患有间质性肺炎。第 272 天,随后的 CT 扫描显示胰腺转移灶消失,原发肿瘤缩小。第 294 天,她接受了腹腔镜左肾切除术。病理分析证实原发肿瘤为 pCR,表明通过手术干预成功根除了 RCC:本病例报告展示了这样一种情况:患者出现了多种严重的虹膜AEs,但仅接受了两个疗程的Ipi + Nivo治疗后,转移灶就消失了。患者最终通过手术治愈并获得了 pCR。该病例突出表明,尽管在使用 Ipi + Nivo 治疗 RCC 期间会出现严重的 irAEs,但可以对其进行适当处理,以最大限度地发挥检查点抑制剂的治疗效果。
{"title":"Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report.","authors":"Ryo Takada, Miki Fujiwara, Masatoshi Maki, Naoyuki Nomura, Shintaro Kono, Akira Fujita, Hiroshi Masumoto, Yoko Takahashi, Yasuhisa Hasegawa, Koji Tamura","doi":"10.1186/s40780-024-00348-8","DOIUrl":"10.1186/s40780-024-00348-8","url":null,"abstract":"<p><strong>Background: </strong>Ipilimumab (Ipi) plus nivolumab (Nivo) is the recommended first-line treatment for renal cell carcinoma (RCC). This report describes a case where pancreatic metastases disappeared after only two courses of Ipi + Nivo therapy. The primary tumor was cured by surgery, and a pathological Complete Response (pCR) was observed despite multiple serious immune-related Adverse Events (irAEs).</p><p><strong>Case presentation: </strong>A 54-year-old woman with RCC and pancreatic metastasis at stage IV, diagnosed with intermediate risk according to the International Metastatic RCC Database Consortium classification, underwent initiation of Ipi + Nivo therapy. On day 26, she developed hyperthyroidism accompanied by tachycardia, leading to the commencement of metoprolol tartrate treatment. Following the resolution of tachycardia, a second course of Ipi + Nivo therapy was administered on day 50. By day 70, the patient exhibited Grade 3 hepatic dysfunction, followed by the onset of hypothyroidism on day 75, necessitating treatment with steroids and levothyroxine. After positive treatment, a Grade 3 skin disorder emerged on day 87 while tapering steroids, prompting treatment with methylprednisolone (mPSL) pulse therapy. The skin disorder responded to steroids, allowing for tapering. However, on day 113, a recurrence of Grade 3 skin disorder occurred, necessitating another mPSL pulse. The patient responded well to treatment, exhibiting improvement in her condition. On day 131, she presented at the hospital with complaints of respiratory distress, prompting a Computed Tomography (CT) scan that revealed interstitial pneumonia. By day 272, subsequent CT imaging showed the disappearance of pancreatic metastasis and shrinkage of the primary tumor. On day 294, she underwent a laparoscopic left nephrectomy. Pathological analysis confirmed a pCR in the primary tumor, indicating successful eradication of RCC through surgical intervention.</p><p><strong>Conclusions: </strong>This case report presents a scenario where multiple severe irAEs appeared in a patient, yet metastases disappeared after only two courses of Ipi + Nivo therapy. The patient was ultimately cured by surgery and achieved a pCR. This case highlights that despite the occurrence of severe irAEs during RCC treatment with Ipi + Nivo therapy, they can be managed appropriately to maximize the therapeutic effects of checkpoint inhibitors.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"26"},"PeriodicalIF":1.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of melatonin on insomnia and daytime sleepiness, in patients with obstructive sleep apnea and insomnia (COMISA): A randomized double-blinded placebo-controlled trial. 褪黑素对阻塞性睡眠呼吸暂停和失眠症(COMISA)患者失眠和白天嗜睡的影响:随机双盲安慰剂对照试验。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-05-30 DOI: 10.1186/s40780-024-00347-9
Tahereh Madani Motlaq, Besharat Rahimi, Shahideh Amini

Background: COMISA is a common disorder that results in nighttime awakenings ,daytime sleepiness and PAP intolerance. Cognitive behavioral therapy for insomnia is used to improve PAP adherence and no medication has been evaluated in such population yet. Melatonin with its chronobiotic and antioxidant effects may have potential benefits on COMISA consequences at the appropriate dose and time. This study aimed to evaluate the effect of melatonin on sleep quality, daytime sleepiness and PAP Compliance in patients with COMISA.

Methods: This double-blind placebo trial randomly assigned eligible OSA patients who suffered from insomnia despite using PAP for over a month to receive either melatonin 10 mg or placebo. The primary outcomes were measured by changes in the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ-10) over one month. Adherence to PAP was measured by the results of the PAP device reports on the average length of time and number of nights that the device was used.

Results: Thirty patients were enrolled in the study after randomization. The melatonin arm showed significant improvement in all four primary outcomes compared to the placebo arm. The PSQI score was 3.836±1.839 in the melatonin arm versus 10.522±3.626 in the placebo arm (Pvalue<0.001). The ISI score was 8.476±3.568 in the melatonin arm versus 14.47±4.50 in the placebo arm (Pvalue<0.001). The ESS score was 6.854±4.334 in the melatonin arm versus 13.298±5.119 in the placebo arm (Pvalue<0.001). The FOSQ-10 score was 24.93±5.02 in the melatonin arm versus 19.87±4.24 in the placebo arm (Pvalue= 0.006). Additionally, nighttime consequences such as sleep latency and awakenings showed significant improvement in the melatonin arm. PAP devices results revealed improvement in duration of PAP use overnight.  CONCLUSIONS: Administering melatonin has been shown to improve self-reported sleep quality and PAP adherence in patients with COMISA.

Trial registration: Registration number IRCT20220105053635N1 was issued by the Iranian Registry of Clinical Trials (IRCT).

背景介绍失眠症(COMISA)是一种常见疾病,会导致夜间惊醒、白天嗜睡和不耐受穿刺前压力机。针对失眠症的认知行为疗法可用于改善患者对 PAP 的依从性,但目前还没有针对此类人群的药物进行过评估。褪黑素具有慢生物钟和抗氧化作用,在适当的剂量和时间服用可能会对 COMISA 的后果产生潜在的益处。本研究旨在评估褪黑素对 COMISA 患者的睡眠质量、白天嗜睡和 PAP 依从性的影响:这项双盲安慰剂试验随机分配符合条件的 OSA 患者接受褪黑素 10 毫克或安慰剂治疗,这些患者在使用 PAP 超过一个月后仍有失眠症状。主要结果通过一个月内匹兹堡睡眠质量指数(PSQI)、失眠严重程度指数(ISI)、埃普沃斯嗜睡量表(ESS)和睡眠功能结果问卷(FOSQ-10)的变化进行测量。使用 PAP 的依从性通过 PAP 设备报告的平均使用时间和夜数的结果来衡量:随机分组后,30 名患者参加了研究。与安慰剂组相比,褪黑素组在所有四项主要结果上都有显著改善。褪黑素组的 PSQI 得分为 3.836±1.839,而安慰剂组为 10.522±3.626(Pvalue试验注册:伊朗临床试验注册中心(IRCT)颁发的注册号为 IRCT20220105053635N1。
{"title":"Effect of melatonin on insomnia and daytime sleepiness, in patients with obstructive sleep apnea and insomnia (COMISA): A randomized double-blinded placebo-controlled trial.","authors":"Tahereh Madani Motlaq, Besharat Rahimi, Shahideh Amini","doi":"10.1186/s40780-024-00347-9","DOIUrl":"10.1186/s40780-024-00347-9","url":null,"abstract":"<p><strong>Background: </strong>COMISA is a common disorder that results in nighttime awakenings ,daytime sleepiness and PAP intolerance. Cognitive behavioral therapy for insomnia is used to improve PAP adherence and no medication has been evaluated in such population yet. Melatonin with its chronobiotic and antioxidant effects may have potential benefits on COMISA consequences at the appropriate dose and time. This study aimed to evaluate the effect of melatonin on sleep quality, daytime sleepiness and PAP Compliance in patients with COMISA.</p><p><strong>Methods: </strong>This double-blind placebo trial randomly assigned eligible OSA patients who suffered from insomnia despite using PAP for over a month to receive either melatonin 10 mg or placebo. The primary outcomes were measured by changes in the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ-10) over one month. Adherence to PAP was measured by the results of the PAP device reports on the average length of time and number of nights that the device was used.</p><p><strong>Results: </strong>Thirty patients were enrolled in the study after randomization. The melatonin arm showed significant improvement in all four primary outcomes compared to the placebo arm. The PSQI score was 3.836±1.839 in the melatonin arm versus 10.522±3.626 in the placebo arm (Pvalue<0.001). The ISI score was 8.476±3.568 in the melatonin arm versus 14.47±4.50 in the placebo arm (Pvalue<0.001). The ESS score was 6.854±4.334 in the melatonin arm versus 13.298±5.119 in the placebo arm (Pvalue<0.001). The FOSQ-10 score was 24.93±5.02 in the melatonin arm versus 19.87±4.24 in the placebo arm (Pvalue= 0.006). Additionally, nighttime consequences such as sleep latency and awakenings showed significant improvement in the melatonin arm. PAP devices results revealed improvement in duration of PAP use overnight.  CONCLUSIONS: Administering melatonin has been shown to improve self-reported sleep quality and PAP adherence in patients with COMISA.</p><p><strong>Trial registration: </strong>Registration number IRCT20220105053635N1 was issued by the Iranian Registry of Clinical Trials (IRCT).</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"25"},"PeriodicalIF":1.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11137944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Health Care and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1